| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA379: Nintedanib for treating idiopathic pulmonary fibrosis and TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted |
|
Medicine details |
|
| Medicine name | nintedanib (Ofev®) |
| Formulation | 100 mg, 150 mg capsule |
| Reference number | 1082 |
| Indication | In adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF). |
| Company | Boehringer Ingelheim Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/02/2015 |
| NICE guidance | TA379: Nintedanib for treating idiopathic pulmonary fibrosis and TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted |